Drug Pricing
Drug Pricing
Advancing Innovation and Access
We analyze the value that therapies bring to patients and develop novel payment models for rewarding innovation while restraining costs.
Featured Research
Most Medicare Beneficiaries May Pay More for Drugs Under the IRA
Part D plans are abruptly shifting more costs onto beneficiaries as they adjust to the IRA’s new cap on out-of-pocket spending.
Experts: Erin Trish
Related Subtopics
The Schaeffer Center is a nationally recognized leader on drug pricing research, with a particular focus on the economic system that distributes and pays for drugs. Our experts develop effective strategies for containing costs while rewarding new treatments based on the value they provide to patients.
Top Drug Pricing Stories View All
Perspective
Trump Admin Takes Pro-Patient Approach to Drug Prices
Featured Experts: Joseph Grogan
In The News View All
Morning Brew
Qato discusses how new PBM reforms may protect pharmacies and patient access
Featured Experts: Dima M. Qato
The New York Times
New York Times cites Schaeffer research on how TV drug ads could benefit consumers
Stateline
Insurer formularies often favor opioid pain medications over non-opioid alternatives, Qato explains
Featured Experts: Dima M. Qato
Los Angeles Times
USC Schaeffer scholars quoted on the rollout of TrumpRx
Featured Experts: Geoffrey Joyce, Darius Lakdawalla
Bloomberg
Lakdawalla argues for a drug pricing system aligned with American values
Featured Experts: Darius Lakdawalla
Featured White Paper
Mitigating the IRA’s Adverse Impacts on the Prescription Drug Market
Although the Inflation Reduction Act of 2022 (IRA) aimed to increase patient access to prescription drugs and decrease spending, researchers warn that it may have unintended negative impacts on patients in the long run. A Schaeffer Center white paper recommends three strategies to mitigate adverse impacts of the IRA.
Read the White PaperTeam View All Drug Pricing Experts
